Document is current
Any future updates will be listed below
-
Authors
Mistretta, Maxime
Cimino, Mena https://orcid.org/0000-0002-8201-729X
Campagne, Pascal
Volant, Stevenn
Kornobis, Etienne https://orcid.org/0000-0001-7712-8270
Hebert, Olivier
Rochais, Christophe https://orcid.org/0000-0001-7996-2082
Dallemagne, Patrick https://orcid.org/0000-0002-4845-615X
Lecoutey, Cédric
Tisnerat, Camille
Lepailleur, Alban
Ayotte, Yann
LaPlante, Steven R. https://orcid.org/0000-0003-2835-5789
Gangneux, Nicolas https://orcid.org/0000-0002-4131-9371
Záhorszká, Monika
Korduláková, Jana https://orcid.org/0000-0003-2834-0165
Vichier-Guerre, Sophie
Bonhomme, Frédéric https://orcid.org/0000-0001-6797-289X
Pokorny, Laura
Albert, Marvin
Tinevez, Jean-Yves
Manina, Giulia https://orcid.org/0000-0001-9905-6095
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-10-LABX-62-IBEID, ANR-21-CE15-0045, ANR-20-PAMR-0005, ANR-21-CE15-0045)
Institut Pasteur
Agentúra na Podporu Výskumu a Vývoja (APVV-19-0189)
- License Information
-
More Information
Article History
Received: 13 March 2024
Accepted: 25 April 2024
First Online: 16 May 2024
Competing interests
: M.M. and G.M. are designated as inventors in the pending international patent application WO 2020/229629 filed by the Institut Pasteur. This patent application covers the multi-condition microfluidic device used for the screening. M.C., P.D., and C.R. are designated as inventors in the pending international patent application WO/2019/138084 filed by the Institut Pasteur, Université de Caen Normandie, and Université Felix Houphouët-Boigny. This patent application covers phenanthroline derivatives. All other authors declare no financial competing interests, and all authors declare no non-financial competing interests.
